GI Effects Comprehensive Stool Profile (Genova)

What is the GI Effects Comprehensive Stool Profile (Genova)?

The GI Effects Comprehensive Stool Profile from BiomarkersLabs.com is a comprehensive multi-domain stool analysis developed and processed by Genova Diagnostics — one of the most established and widely respected specialist functional laboratory platforms in the USA, with over 35 years of experience in gastrointestinal and functional medicine testing. The GI Effects Comprehensive Stool Profile combines three distinct analytical methodologies in a single specimen collection: quantitative PCR (qPCR) for accurate microorganism identification and quantification, culture-based analysis for antibiotic and antifungal sensitivity reporting, and microscopy for parasite and morphological assessment — delivering a more analytically complete picture than any single methodology alone. Genova’s integrated reporting format presents the full multi-domain GI result set within a clinical interpretive framework specifically designed for functional and integrative medicine practitioners, including annotated reference ranges, gut health scoring, and clear clinical context for each result. Specimens are processed through Genova Diagnostics’ CLIA-certified USA laboratory. Results are delivered to your secure BiomarkersLabs.com practitioner portal within 14–21 business days of specimen receipt. Available in USA and Canada. Licensed practitioners only.

The GI Effects Comprehensive Stool Profile is distinguished from the GI-MAP (BML-GAS-001) by its analytical methodology combination and its Genova reporting platform. Where the GI-MAP uses exclusively qPCR methodology, the GI Effects combines qPCR with traditional culture for organisms where sensitivity testing is clinically relevant — particularly for dysbiotic bacteria and yeast where antibiotic or antifungal susceptibility data directly guides treatment selection. A patient with significant Candida overgrowth identified by the GI Effects receives a culture-derived sensitivity profile showing which antifungal agents the specific Candida strain is susceptible to — information that guides targeted treatment selection rather than empirical therapy. Similarly, dysbiotic bacterial overgrowth with sensitivity data enables targeted herbal or pharmaceutical antimicrobial selection. This combined methodology approach reflects Genova’s clinical philosophy of providing not just diagnostic identification but treatment-guiding data within the same test result. Practitioners who use Genova’s integrated reporting platform across multiple test categories — including Genova’s hormone, nutritional, and metabolic assessments — and who value the consistency of Genova’s interpretive framework and patient-facing report format should consider the GI Effects as their primary comprehensive stool analysis platform.

The GI Effects Comprehensive Stool Profile covers five clinical domains in a single specimen: microbiome composition (beneficial and pathogenic bacteria, yeast, and parasites), digestive function (elastase-1, fecal fat, and short-chain fatty acids), gut immune function (secretory IgA), intestinal inflammation (calprotectin and eosinophil protein X), and intestinal permeability (zonulin). This multi-domain coverage provides a holistic assessment of GI health that goes substantially beyond infection screening or microbiome profiling alone — identifying the interplay between microbiome dysbiosis, digestive dysfunction, immune compromise, and barrier permeability that drives many complex chronic GI and systemic conditions. Licensed practitioners only through BiomarkersLabs.com.

What does this panel measure?

Microbiome and Pathogen Assessment — qPCR-based quantification of key commensal and pathogenic bacteria, yeast (including Candida species with sensitivity profiling by culture), H. pylori, parasites, and opportunistic pathogens. Culture-based sensitivity testing for dysbiotic organisms where antimicrobial guidance is clinically relevant.

Digestive Function Markers — Elastase-1 (exocrine pancreatic enzyme output, reflecting pancreatic digestive sufficiency), Fecal Fat (fat malabsorption assessment), and Short-Chain Fatty Acids (SCFA — butyrate, propionate, and acetate quantification reflecting microbial fermentation capacity and colonocyte fuel supply).

Gut Immune Markers — Secretory IgA (sIgA — mucosal immune competence marker; reduced sIgA indicates impaired gut immunological defence).

Intestinal Inflammatory Markers — Calprotectin (neutrophil-derived marker of mucosal inflammation — elevated in IBD, infection, and significant mucosal injury) and Eosinophil Protein X (EPX — eosinophilic inflammation marker relevant to allergic and parasitic gut inflammation).

Intestinal Permeability Marker — Zonulin (a tight junction regulatory protein whose elevation in stool reflects intestinal barrier dysfunction and increased intestinal permeability).

Clinical indications

Comprehensive gastrointestinal function assessment via the Genova platform — the profile simultaneously characterises microbiome composition, digestive function, gut immune status, mucosal inflammation, and intestinal permeability in a single specimen through Genova’s integrated reporting framework.

Chronic GI symptoms requiring full microbiome and digestive function workup — patients with chronic bloating, altered bowel habit, abdominal discomfort, malabsorption symptoms, or unexplained GI symptoms benefit from the comprehensive multi-domain assessment this profile provides.

Gut dysbiosis assessment with inflammation and digestive markers — the combination of dysbiosis identification, inflammatory marker quantification, and digestive function assessment enables the practitioner to understand whether GI symptoms are driven by microbial, inflammatory, or functional digestive mechanisms — or a combination of all three.

Functional medicine baseline gut assessment — the GI Effects Comprehensive profile is one of the most widely ordered baseline GI assessments in functional medicine practice, establishing a comprehensive multi-domain gut health baseline before initiating probiotic, antimicrobial, or dietary GI restoration protocols.

Practitioners using Genova integrated reporting — practitioners who routinely use Genova Diagnostics for hormone, nutritional, metabolic, or other functional tests benefit from the consistency of Genova’s interpretive framework, clinical commentary, and patient-facing report format across their full test catalogue.

Post-antibiotic gut microbiome and digestive function recovery assessment — monitoring microbiome restoration, beneficial organism recolonisation, secretory IgA recovery, and SCFA production after antibiotic treatment provides objective evidence of gut ecosystem recovery.

Short-chain fatty acid assessment for colonocyte health and microbiome fermentation capacity — SCFA quantification is uniquely available through the GI Effects and provides insight into the health of the microbial fermentation ecosystem and its capacity to produce butyrate — the primary fuel for colonocytes and a key regulator of intestinal barrier integrity and immune homeostasis.

Eosinophilic gut inflammation assessment — elevated EPX identifies eosinophilic mucosal inflammation relevant to food allergy, parasitic infection, and eosinophilic GI disorders — a dimension absent from calprotectin-only inflammatory assessment.

Sample type and collection

Sample Type: Stool

Fasting Required: No — no fasting is required. The patient collects a stool specimen using the Genova Diagnostics collection kit dispatched after the order is placed.

Collection Method: Home stool collection using the Genova Diagnostics collection kit with detailed collection instructions, collection devices, preservation solutions, and pre-paid return shipping.

Specimen Timing Note: Discontinue probiotics for 2 weeks before collection. Discontinue antibiotics and antifungal agents for 4 weeks before collection. Bismuth preparations should be avoided for 2 weeks. For accurate short-chain fatty acid and fecal fat assessment, maintain the patient’s normal diet for the 3–5 days preceding collection.

Turnaround time

14–21 business days from specimen receipt at Genova Diagnostics. The ordering practitioner receives an automated email notification when results are available. Results are never sent to the patient.

Availability

USA · Canada. This test is processed by Genova Diagnostics’ CLIA-certified USA laboratory network.

This test does not carry a New York state restriction.

Compliance and certifications

CLIA Certified — All specimens processed by Genova Diagnostics’ CLIA-certified USA laboratories.

HIPAA Compliant — USA patient data handled in full compliance with HIPAA.

PIPEDA Compliant — Canadian data handled in compliance with PIPEDA.

How to order

This test is available exclusively to licensed healthcare practitioners. Register free at BiomarkersLabs.com. Once active, search for the GI Effects Comprehensive Stool Profile (Genova) in your portal, enter patient details, and submit the order. A Genova collection kit is dispatched to the patient. Results are returned within 14–21 business days. No subscription required, pay per test.

This test is available exclusively to licensed healthcare practitioners. Results are delivered to the ordering practitioner’s secure portal only — never directly to patients. BiomarkersLabs.com does not accept patient self-referrals.

Frequently Asked Questions — GI Effects Comprehensive Stool Profile (Genova)

How does the GI Effects differ from the GI-MAP (BML-GAS-001)?

Both are comprehensive stool analysis platforms but differ in methodology and reporting. The GI-MAP uses exclusively qPCR for all organisms and markers. The GI Effects combines qPCR with traditional culture — providing antimicrobial and antifungal sensitivity data for dysbiotic organisms that guides targeted treatment selection. The GI Effects also uniquely includes short-chain fatty acid quantification and eosinophil protein X. The GI-MAP uses Diagnostic Solutions’ reporting platform; the GI Effects uses Genova’s integrated framework. The choice between them depends on whether culture-derived sensitivity data and Genova platform integration are priorities.

What are short-chain fatty acids and why are they clinically important?

Short-chain fatty acids (SCFAs) — primarily butyrate, propionate, and acetate — are produced by colonic bacteria during fermentation of dietary fibre. Butyrate is the primary energy source for colonocytes and is a critical regulator of intestinal barrier integrity, mucosal immune function, and anti-inflammatory signalling. Low butyrate production reflects reduced beneficial fibre-fermenting bacteria (particularly Bifidobacterium, Faecalibacterium prausnitzii, and Akkermansia muciniphila) and is associated with impaired colonocyte health, increased intestinal permeability, and chronic GI inflammation. SCFA quantification provides a unique functional readout of the microbiome’s metabolic contribution to gut health that organismal abundance data alone does not capture.

Is the GI Effects available for patients in New York state?

Yes. This test does not carry a New York state restriction.